227 related articles for article (PubMed ID: 31582358)
1. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD;
Lancet Respir Med; 2019 Nov; 7(11):951-963. PubMed ID: 31582358
[TBL] [Abstract][Full Text] [Related]
2. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
ITAC (INSIGHT 013) Study Group
Lancet; 2022 Feb; 399(10324):530-540. PubMed ID: 35093205
[TBL] [Abstract][Full Text] [Related]
3. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT;
Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360
[TBL] [Abstract][Full Text] [Related]
4. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
[TBL] [Abstract][Full Text] [Related]
5. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
[TBL] [Abstract][Full Text] [Related]
7. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
Brown SM; Barkauskas CE; Grund B; Sharma S; Phillips AN; Leither L; Peltan ID; Lanspa M; Gilstrap DL; Mourad A; Lane K; Beitler JR; Serra AL; Garcia I; Almasri E; Fayed M; Hubel K; Harris ES; Middleton EA; Barrios MAG; Mathews KS; Goel NN; Acquah S; Mosier J; Hypes C; Salvagio Campbell E; Khan A; Hough CL; Wilson JG; Levitt JE; Duggal A; Dugar S; Goodwin AJ; Terry C; Chen P; Torbati S; Iyer N; Sandkovsky US; Johnson NJ; Robinson BRH; Matthay MA; Aggarwal NR; Douglas IS; Casey JD; Hache-Marliere M; Georges Youssef J; Nkemdirim W; Leshnower B; Awan O; Pannu S; O'Mahony DS; Manian P; Awori Hayanga JW; Wortmann GW; Tomazini BM; Miller RF; Jensen JU; Murray DD; Bickell NA; Zatakia J; Burris S; Higgs ES; Natarajan V; Dewar RL; Schechner A; Kang N; Arenas-Pinto A; Hudson F; Ginde AA; Self WH; Rogers AJ; Oldmixon CF; Morin H; Sanchez A; Weintrob AC; Cavalcanti AB; Davis-Karim A; Engen N; Denning E; Taylor Thompson B; Gelijns AC; Kan V; Davey VJ; Lundgren JD; Babiker AG; Neaton JD; Lane HC;
Lancet Respir Med; 2023 Sep; 11(9):791-803. PubMed ID: 37348524
[TBL] [Abstract][Full Text] [Related]
8. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Marty FM; Vidal-Puigserver J; Clark C; Gupta SK; Merino E; Garot D; Chapman MJ; Jacobs F; Rodriguez-Noriega E; Husa P; Shortino D; Watson HA; Yates PJ; Peppercorn AF
Lancet Respir Med; 2017 Feb; 5(2):135-146. PubMed ID: 28094141
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
[TBL] [Abstract][Full Text] [Related]
16. INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.
INSIGHT FLU005 IVIG Pilot Study Group
J Infect Dis; 2016 Feb; 213(4):574-8. PubMed ID: 26374911
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N;
Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975
[TBL] [Abstract][Full Text] [Related]
20. Hyperimmune immunoglobulin for people with COVID-19.
Kimber C; Valk SJ; Chai KL; Piechotta V; Iannizzi C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD015167. PubMed ID: 36700518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
